phase readout
saveNCT05345171: Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency
ACTIVE_NOT_RECRUITINGupdated 14d ago
community read0 votes
Sponsor: Ultragenyx Pharmaceutical Inc. Phase: PHASE3. Conditions: OTC Deficiency
view source ↗
comments(0)
5-min edit window · permanent after that